---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002822"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:46:31.934163+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sarepta prelim FY2023 net product rev $1.145B; ELEVIDYS $200.4M beats consensus

## Summary
- Preliminary FY2023 total net product revenue of ~$1.145B; RNA PMOs $945.0M (above $925M guidance).
- ELEVIDYS net product revenue of $131.3M in Q4 and $200.4M for FY2023, significantly exceeding consensus.
- RNA-based PMO net revenue of $234.3M in Q4 and $945.0M for FY2023.
- Preliminary cash, equivalents, restricted cash and investments of ~$1.7B as of Dec 31, 2023.
- Company to report final Q4/FY2023 results in late February 2024; results subject to adjustment.

## SEC filing metadata
- accession: 0000950170-24-002822
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000095017024002822/0000950170-24-002822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000095017024002822/srpt-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002822
- JSON: https://secwatch.observer/filing/0000950170-24-002822.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002822.txt

## Key facts
- Earnings Releases
  Sarepta Therapeutics, Inc. reported the year ended December 31, 2023 results: revenue $1.145 billion.
  - Period: the year ended December 31, 2023
  - Revenue: $1.145 billion
  - Result: preliminary results
  source text: the Company disclosed its (unaudited) cash position of approximately $1.7 billion as of December 31, 2023, and that the Company generated approximately $1.145 billion in total net product revenue (unaudited) in the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000095017024002822/0000950170-24-002822-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.